Study reveals differences in malaria clearance between males and females

October 27, 2020

Females are able to clear asymptomatic malaria infections at a faster rate than their male counterparts, says a study published today in eLife.

The findings, originally posted on the preprint server medRxiv*, suggest that biological sex-based differences are an important factor for epidemiologists to consider in the human response to malaria parasites.

Malaria remains a significant global health challenge, with infections causing disease symptoms that range from uncomplicated to severe. Additionally, asymptomatic malaria infections are common in places where the disease occurs most often, known as endemic areas. Due to partial immunity, individuals can carry parasites for long periods of time while unaware that they are infected.

It is well established that chronic asymptomatic infection with the most common and fatal malaria parasite, Plasmodium falciparum (P. falciparum), can cause morbidity in those infected and contribute to ongoing disease transmission. As these infections represent an important part of the parasite reservoir and are therefore a major obstacle for efforts to eliminate malaria, characterising them is crucial.

"While it is widely recognised that pregnant women have increased susceptibility to malaria infection and more severe outcomes, less attention has been paid to the possibility of other biological sex differences in malaria immunity," says lead author Jessica Briggs, Clinical Fellow in Infectious Diseases, UC San Francisco, US. "This is despite multiple studies demonstrating males are more frequently found to be infected when you go out and check in a community."

Understanding the immune response of humans to chronic P. falciparum infection requires frequent follow up of infected individuals, sensitive detection of parasites, and the ability to distinguish 'superinfection' from a persistent infection. Superinfection is common in endemic areas and refers to an individual acquiring a new infection when they are already infected.

In their study, Briggs and the team followed a representative group of people living in a malaria-endemic area of eastern Uganda. Using a genetic sequencing technique called amplicon deep-sequencing, they estimated both the rate of new infections and duration of chronic asymptomatic malaria infections in the group and compared these measures by sex.

Previous studies have reported a higher prevalence of malaria infection in males compared to females, which was also seen in this cohort. Since females had a lower prevalence of infection, but a similar rate of new infections compared to males, the team looked at whether there was a difference between the sexes in how quickly they were able to clear infections. "Our analysis revealed that asymptomatic infections cleared naturally - as in, when individuals were not treated by antimalarials - at nearly twice the rate in females versus males," Briggs says.

The authors add that these findings come with some limitations. For example, as co-senior author Isabel Rodriguez-Barraquer, Assistant Professor of Medicine at UC San Francisco, says: "There may be other unmeasured factors that affect our results, such as genetic differences or sex-based differences in the use of unreported outside antimalarials."

Despite these limitations, the authors say their findings should encourage scientists to better characterise sex-based differences in malaria. "Our next job is to unearth the underlying biological explanations for these sex-based differences in the human response to malaria," concludes co-senior author Bryan Greenhouse, Associate Professor of Medicine at UC San Francisco. "We have just begun a systems-based approach to comprehensively evaluate the immune response over time in a new study based in Uganda."

The paper 'Sex-based differences in clearance of chronic Plasmodium falciparum infection' can be freely accessed online at
Contents, including text, figures and data, are free to reuse under a CC BY 4.0 license.

*This study was originally published on medRxiv, at

Media contact

Emily Packer, Media Relations Manager
eLife 01223 855373

About eLife

eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We work across three major areas: publishing, technology and research culture. We aim to publish work of the highest standards and importance in all areas of biology and medicine, including Epidemiology and Global Health and Microbiology and Infectious Disease, while exploring creative new ways to improve how research is assessed and published. We also invest in open-source technology innovation to modernise the infrastructure for science publishing and improve online tools for sharing, using and interacting with new results. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at

To read the latest Epidemiology and Global Health research published in eLife, visit

And for the latest in Microbiology and Infectious Disease, see


Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to